2. Chwastiak LA, Ehde DM. Psychiatric issues in multiple sclerosis. Psychiatry Clin N Am 2007;30:803-817.
3. José Sá M. Psychological aspects of multiple sclerosis. Clin Neurol Neurosurg 2008;110:868-877.
5. Boeije HR, Duijnstee MS, Grypdonck MH, Pool A. Encountering the downward phase: biographical work in people with multiple sclerosis living at home. Soc Sci Med 2002;55:881-893.
6. Butler MA, Bennett TL. In search of a conceptualization of multiple sclerosis: a historical perspective. Neuropsychol Rev 2003;13:93-112.
8. Ombredane A. Les Troubles Mentaux de la Sclérose en Plaques. Paris: Presses Universitaires de France; 1929.
10. Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry 1987;9:426-434.
11. Sullivan MFI, Weinshenker B, Mikai S, Edgley K. Depression before and after diagnosis of multiple sclerosis. Mult Scler 1995;1:104-108.
12. Possa MF, Minacapelli E, Canale S, Comi G, Martinelli V, Falautano M. The first year after diagnosis: psychological impact on people with multiple sclerosis. Psychol Health Med 2017;22:1063-1071.
13. Noy S, Achiron A, Gabbay U, Barak Y, Rotstein Z, Laor N, SarovaPinhas I. A new approach to affective symptoms in relapsing-remitting multiple sclerosis. Compr Psychiatry 1995;36:390-395.
14. Pujol J, Bello J, Deus J, Martí-Vilalta JL, Capdevila A. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology 1997;49:1105-1110.
15. Bakshi R, Czarnecki D, Shaikh ZA, Priore RL, Janardhan V, Kaliszky Z, et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport 2000;11:1153-1158.
16. Gobbi C, Rocca MA, Riccitelli G, Pagani E, Messina R, Preziosa P, et al. Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. Mult Scler 2014;20:192-201.
17. Gold SM, O’Connor MF, Gill R, Kern KC, Shi Y, Henry RG, et al. Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling. Hum Brain Mapp 2014;35:30-37.
19. Kern S, Schultheiss T, Schneider H, Schrempf W, Reichmann H, Ziemssen T. Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis. Psychoneuroendocrinology 2011;36:1505-1512.
20. Fassbender K, Schmidt R, Mössner R, Kischka U, Kühnen J, Schwartz A, et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis. Arch Neurol 1998;55:66-72.
21. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-533.
22. Mohr DC, Likosky W, Dwyer P, Van Der Wende J, Boudewyn AC, Goodkin DE. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis. Arch Neurol 1999;56:1263-1265.
23. Patten SB, Metz LM. Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology 2002;59:744-746.
24. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, et al. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. Mult Scler 2011;17:991-1001.
25. Mohr DC, Goodkin DE, Gatto N, Van Der Wende J. Depression, coping and level of neurological impairment in multiple sclerosis. Mult Scler 1997;3:254-258.
26. Randolph JJ, Arnett PA, Higginson CI, Voss WD. Neurovegetative symptoms in multiple sclerosis: relationship to depressed mood, fatigue, and physical disability. Arch Clin Neuropsychol 2000;15:387-398.
28. Brenner P, Piehl F. Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions. Acta Neurol Scand 2016;134:47-54.
30. Rasmussen KG, Keegan BM. Electroconvulsive therapy in patients with multiple sclerosis. J ECT 2007;23:179-180.
31. Tarrants M, Oleen-Burkey M, Castelli-Haley J, Lage MJ. The impact of comorbid depression on adherence to therapy for multiple sclerosis. Mult Scler Int 2011;2011:1-10.
32. Mullins LL, Cote MP, Fuemmeler BF, Jean VM, Beatty WW, Paul RH. Illness intrusiveness, uncertainty, and distress in individuals with multiple sclerosis. Rehabil Psychol 2001;46:139-153.
33. Pompili M, Forte A, Palermo M, Stefani H, Lamis DA, Serafini G, et al. Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res 2012;73:411-417.
34. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002;59:674-678.
35. Buhse M. Assessment of caregiver burden in families of persons with multiple sclerosis. J Neurosci Nurs 2008;40:25-31.
37. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 2007;13:67-72.
38. Lin A, Chen F, Liu F, Li Z, Liu Y, Lin S, et al. Regional gray matter atrophy and neuropsychologcal problems in relapsing-remitting multiple sclerosis. Neural Regen Res 2013;8:1958-1965.
39. Paparrigopoulos T, Ferentinos P, Kouzoupis A, Koutsis G, Papadimitriou GN. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry 2010;22:14-21.
40. Honarmand K, Feinstein A. Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients. Mult Scler 2009;15:1518-1524.
42. Feinstein A, Du Boulay G, Ron MA. Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. Brit J Psychiatry 1992;161:680-685.
43. Sidhom Y, Ben Djebara M, Hizem Y, Abdelkefi I, Kacem I, Gargouri A, et al. Bipolar disorder and multiple sclerosis: a case series. Behav Neurol 2014;2014:1-4.
44. Pinkston JB, Kablinger A, Alekseeva N. Multiple sclerosis and behavior. Int Rev Neurobiol 2007;79:323-339.
45. Kosmidis MH, Giannakou M, Messinis L, Papathanasopoulos P. Psychotic features associated with multiple sclerosis. Int Rev Psychiatry 2010;22:55-66.
46. Fricchione GL, Carbone L, Bennett WI. Psychotic disorders caused by a general medical condition, with delusions. Secondary ‘organic’ delusional syndromes. Psychiatr Clin North Am 1995;18:363-378.
48. Sperner-Unterweger B, Fuchs D. Schizophrenia and psychoneuroimmunology. Curr Opin Psychiatry 2015;28:201-206.
49. Goeb JL, Cailleau A, Laine P, Etcharry-Bouyx F, Maugin D, Duverger P, et al. Acute delirium, delusion and depression during INF-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol 2003;26:5-7.
50. Harel Y, Barak Y, Achiron A. Dysregulation of affect in multiple sclerosis: new phenomenological approach. Psychiatry Clin Neurosci 2007;61:94-98.
51. Benedict RH, Priore RL, Miller C, Munschauer F, Jacobs L. Personality disorder in multiple sclerosis correlates with cognitive impairment. J Neuropsychiatry Clin Neurosci 2001;13:70-76.
53. Roy S, Drake A, Fuchs T, Dwyer MG, Zivadinov R, Chapman BP, et al. Longitudinal personality change associated with cognitive decline in multiple sclerosis. Mult Scler 2018;[Epub ahead of print].
54. Sullivan LE, Fiellin DA, O’Connor PG. The prevalence and impact of alcohol problems in major depression: a systematic review. Am J Med 2005;118:330-341.
55. Lechtenberg R. Multiple Sclerosis Fact Book. 2nd Edition. Philadelphia: FA Davis; 1995.
56. Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler 2006;12:646-651.
57. Feinstein A, Feinstein K, Gray T, O’Connor P. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 1997;54:1116-1121.
58. Minden SL, Schiffer RB. Affective disorders in multiple sclerosis. Arch Neurol 1990;47:98-104.
60. Seliger GM, Hornstein A. Serotonin, fluoxetine, and pseudobulbar affect. Neurology 1989;39:1400-1400.
61. Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, et al. Randomized controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006;59:780-787.
62. Rabins PV. Euphoria in Multiple Sclerosis. In: Rao SM, editor. Neurobehavioural Aspects of Multiple Sclerosis. New York: Oxford University Press, 1990, p. 180-185.
64. Reuter F, Zaaraoui W, Crespy L, Faivre A, Rico A, Malikova I, et al. Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;82:1157-1159.
69. Sperling RA, Guttmann CR, Hohol MJ, Warfield SK, Jakab M, Parente M, et al. Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. Arch Neurol 2001;58:115-121.
70. Hulst HE, Steenwijk MD, Versteeg A, Pouwels PJ, Vrenken H, Uitdehaag BM, et al. Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions. Neurology 2013;80:1025-1032.
71. Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009;66:1144-1150.
72. Schoonheim MM, Hulst HE, Brandt RB, Strik M, Wink AM, Uitdehaag BM, et al. Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. Neurology 2015;84:776-783.
73. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008;7:1139-1151.
74. Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur Neurol 2002;47:11-14.
75. Zéphir H, De Seze J, Dujardin K, Dubois G, Cabaret M, Bouillaguet S, et al. One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. Mult Scler 2005;11:360-363.
76. Penner IK. Evaluation of cognition and fatigue in multiple sclerosis: daily practice and future directions. Acta Neurol Scand 2016;134(Suppl 200):19-23.
79. Nebel K, Wiese H, Seyfarth J, Gizewski ER, Stude P, Diener HC, et al. Activity of attention related structures in multiple sclerosis. Brain Res 2007;1151:150-160.
80. Rao SM, Grafman J, DiGuilio D, Mittenberg W, Bernardin L, Leo GJ, et al. Memory dysfunction in multiple sclerosis: its relation to working memory, semantic encoding and implicit learning. Neuropsychology 1993;7:364-374.
81. Thornton AE, Raz N, Tucke KA. Memory in multiple sclerosis: contextual encoding deficits. J Int Neuropsychol Soc 2002;8:395-409.
82. Grossman M, Robinson KM, Onishi K, Thompson H, Cohen J, D’Esposito M. Sentence comprehension in multiple sclerosis. Acta Neurol Scand 1995;92:324-331.
83. Rao SM. Neuropsychology of multiple sclerosis. Curr Opin Neurol 1995;8:216-220.
84. Vleugels L, Lafosse C, Van Nunen A, Charlier M, Ketelaer P, Vandenbussche E. Visuoperceptual impairment in MS patients: nature and possible neural origins. Mult Scler 2001;7:389-401.
85. Rao SM. Neuropsychological Aspects of Multiple Sclerosis. In: Raine CS, editor. Multiple Sclerosis: Clinical and Pathogenic Basis. London: Chapman and Hall, 1997, p. 365-372.
86. Guidelines MSCP. Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis. Washington D.C: Paralyzed Veterans of America; 1998.
87. Russo M, Calamuneri A, Cacciola A, Bonanno L, Naro A, Dattola V, et al. Neural correlates of fatigue in multiple sclerosis: a combined neurophysiological and neuroimaging approach (R1). Arch Ital Biol 2017;155:142-151.
88. Finke C, Schlichting J, Papazoglou S, Scheel M, Freing A, Soemmer C, et al. Altered basal ganglia functional connectivity in multiple sclerosis patients with fatigue. Mult Scler 2015;21:925-934.
89. Krupp LB, Christodoulou C. Fatigue in multiple sclerosis. Curr Neurol Neurosci Rep 2001;1:294-298.
90. Karatepe AG, Kaya T, Günaydn R, Demirhan A, Ce P, Gedizlioğlu M. Quality of life in patients with multiple sclerosis: the impact of depression, fatigue, and disability. Int J Rehabil Res 2011;34:290-298.
91. Lobentanz IS, Asenbaum S, Vass K, Sauter C, Klösch G, Kollegger H, et al. Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 2004;110:6-13.
92. Bakshi R, Shaikh ZA, Miletich RS, Czarnecki D, Dmochowski J, Henschel K, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000;6:181-185.
93. Mohr DC, Hart SL, Goldberg A. Effects of treatment for depression on fatigue in multiple sclerosis. Psychosom Med 2003;65:542-547.
95. Çelik DB, Poyraz EÇ, Bingöl A, Idiman E, Ozakbaş S, Kaya D. Sexual dysfunction ın multiple sclerosis: gender differences. J Neurol Sci 2013;324:17-20.
97. Zorzon M, Zivadinov R, Locatelli L, Stival B, Nasuelli D, Bratina A, et al. Correlation of sexual dysfunction and brain magnetic resonance imaging in multiple sclerosis. Mult Scler 2003;9:108-110.
99. Tan-Kristanto S, Kiropoulos LA. Resilience, self-efficacy, coping styles and depressive and anxiety symptoms in those newly diagnosed with multiple sclerosis. Psychol Health Med 2015;20:635-645.